relacorilant FDA approval date

The FDA approved relacorilant (CORT125134) on 25 Mar 2026.

FDA approval date
25 Mar 2026

Drug identity checked against registry records

Also recorded as CORT125134

Included trials

TrialSponsorPhaseStatusPrimary completion
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing SyndromeNCT03604198Corcept TherapeuticsPhase 2Active not recruiting2026-12Estimated

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2026-03-25DayrelacorilantFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA220641", "applicant_as_listed_by_fda": "CORCEPT THERAP", "brand_names": ["LIFYORLI (COPACKAGED)"], "active_ingredients": ["RELACORILANT"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20260325", "matched_on": "drug name equals FDA sole active ingredient"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026